NCT05303519Phase 3Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Study sponsor: Nuvation Bio Inc. · NUVB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12-01Estimated
Enrollment · participants365Estimated
Source updated2026-11-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0. After: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 Measure: Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0.

Planned enrollment increased by 240 participants

Before: 125 participants (planned). After: 365 participants (planned).

Primary completion date changed

Before: 1 Dec 2027. After: 1 Dec 2028.

Phase changed

Before: PHASE2. After: PHASE3.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview